Lumida
/SNDX
⌘K
Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

SNDX
$18.18USD-3.40%-0.64 today

MARKET CAP

1.6B

P/E (TTM)

FWD P/E

DAY RANGE

$18 – $19

52W RANGE

$13
$26

AI Summary

Stalk
Sell NowMedium

The stock failed its key support cluster near earlier lows and now trades below all major EMAs, signaling a breakdown rather than a pullback. The medium-term structure is bearish with further downside likely as supply overwhelms demand, and short-term price momentum confirms unfavorable timing. We are selling now into the continued decline, targeting participation in the accelerating down move.

  • Revuforj and Niktimvo generate ~$200M annually, validating commercial viability
  • Upcoming clinical data readouts could act as major growth catalysts
  • Profit margins are deeply negative and earnings yield remains below zero
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2019FY 2020FY 2021FY 2024FY 2025TREND
Sales, Adj.$1.5M$1.5M$139.7M$23.7M$172.4M
YoY %+9109.6%+627.8%
P / Sales176.5x605.6x8.4x47.8x10.6x
EV / Sales181.3x561.6x7.1x59.7x12.5x
Gross Profit, Adj.$1.5M$1.5M$139.7M$22.9M$165.4M
YoY %+9109.6%+623.6%
Margin %100.0%100.0%100.0%96.5%96.0%
EV / Gross Profit181.3x561.6x7.1x61.9x13.0x
EBITDA, Adj.$-57.4M$-71.3M$26.3M$-339.7M$-273.1M
YoY %+24.2%-24.2%+136.8%-47.7%+19.6%
Margin %-3786.9%-4702.3%18.8%-1434.4%-158.4%
EV / EBITDA-4.8x-11.9x37.8x-4.2x-7.9x
EBIT$-57.5M$-71.4M$26.2M$-339.7M$-273.1M
YoY %+24.2%-24.1%+136.7%-47.7%+19.6%
Margin %-3792.9%-4708.2%18.8%-1434.4%-158.4%
EV / EBIT-4.8x-11.9x37.9x-4.2x-7.9x
Net Income$-56.0M$-77.1M$24.9M$-318.8M$-285.4M
YoY %+24.2%-37.5%+132.3%-52.3%+10.5%
Net Margin-3694.6%-5080.0%17.8%-1346.1%-165.6%
EPS (GAAP)-$1.84-$1.87$0.46-$3.72-$3.29
YoY %+37.0%-1.6%+124.6%-24.8%+11.6%